Microsoft Corporation (NASDAQ:MSFT), Flexion Therapeutics, Inc. (NYSE:FLXN)

Lester Mason
October 13, 2017

Flexion Therapeutics (NASDAQ:FLXN) has a market cap of $834.16 Million and the number of outstanding shares have been calculated 31.83 Million. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.

Several other brokerages have also recently weighed in on FLXN. Zacks Investment Research cut shares of Flexion Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, August 22nd. Royal Bank Of Canada reissued a "buy" rating and set a $44.00 price target on shares of Flexion Therapeutics in a research report on Friday, July 7th. Cantor Fitzgerald set a $40.00 target price on shares of Flexion Therapeutics and gave the company a buy rating in a research report on Monday, June 12th.

In terms of EBITDA Yield, Flexion Therapeutics, Inc. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

Flexion Therapeutics (NASDAQ:FLXN) opened at 26.21 on Tuesday.

This company shares (CBAK) so far managed to recover 57.74% since collapsing to its 52-week low. The stock's last price was higher from the average trading price of 50 days recorded at $24.17 while enlarging the period to 200 trading days, the average price was $21.75. (NasdaqGM:FLXN) is -0.098078. This is calculated by taking the earnings per share and dividing it by the last closing share price. (CBAK) remained unsuccessful in beating the consensus-estimated -$0.2 as it actually earned -$0.3 per share in its last reported financial results. If the published price targets set by Teladoc, Inc. analysts have any power to influence the stock's share price, the highest price target set for TDOC is $48.

TRADEMARK VIOLATION NOTICE: "Flexion Therapeutics, Inc. (FLXN) Earns "Outperform" Rating from BMO Capital Markets" was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another site, it was stolen and republished in violation of US and global trademark & copyright law. The Return on Assets for Flexion Therapeutics, Inc.

In other Flexion Therapeutics news, insider Yamo Deniz acquired 3,000 shares of the stock in a transaction on Friday, September 1st. The stock was purchased at an average cost of $24.15 per share, with a total value of $72,450.00. That is, the BTM is a comparison of a company's net asset value per share to its share price. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively. The stock price hovered in an intraday range of $75.95- $76.46.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business.

For the Current Quarter, the growth estimate for Flexion Therapeutics, -46.2%, while for the Next Quarter the stock growth estimate is -41.2%. The company has Beta Value of 1.11 and ATR value of 1.83. As of the end of the quarter Raymond James Financial Services Advisors, Inc. had acquired a total of 7,667 shares growing its position 13.7%. Asset Management One Co. Finally, BB&T Securities LLC acquired a new position in Flexion Therapeutics during the second quarter worth $289,000. Voya Investment Management LLC lifted its holdings in Flexion Therapeutics by 25.8% during the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company's stock valued at $105,000 after purchasing an additional 3,500 shares during the last quarter.

The Leverage Ratio of Flexion Therapeutics, Inc. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain.

Other reports by Iphone Fresh

Discuss This Article